| Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Is blood transfusion safe during the COVID-19 pandemic? |
|
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
| Targeting the Microenvironment in MDS: The Final Frontier |
|
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
| How we diagnose Myelodysplastic syndromes |
|
Frontiers in Oncology |
Myelodysplastic Syndromes (MDS) |
| The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
|
Frontiers in Oncology |
Aplastic Anemia |
| Novel therapeutic choices in immune aplastic anemia |
|
F1000Research |
Aplastic Anemia |
| Management of aplastic anemia after failure of frontline immunosuppression |
|
Expert Review of Hematology |
Aplastic Anemia |
| Getting personal with myelodysplastic syndromes: is now the right time? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
